In this second issue of our newsletter you’ll find some research highlights from our Covid-NMA project.

Living systematic review
We are searching the literature every day and collecting data for each RCT and non-RCT of COVID-19 treatment identified. We have currently included 30 RCTs representing 28 treatment comparisons and 18 non randomized studies representing 10 treatment comparisons.

For each treatment comparison we provide forest plots for all the outcomes of interest available, a Summary of Findings (SoF) table and a detailed description of primary studies, including a risk of bias assessment. We update the evidence synthesis every Friday.

We have created network diagrams of RCTs evaluating pharmacological treatments describing the amount of evidence and the respective risk of bias for the different interventions (represented by nodes) and their comparison (represented by lines) for a given outcome.

Contact of authors
In collaboration with the WHO, we have contacted several authors of incomplete studies and of complete studies with unpublished results in order to ask them for essential information about outcome data and the conduct and findings of these studies, with the aim of accurately representing them in our evidence synthesis.
This process is ongoing but we have already received a number of responses that allowed us to update the information of 5 studies, corresponding to 6 treatment comparisons.

Contact of investigators of registered trials
In collaboration with the WHO, we have contacted investigators of ongoing trials registered in the ICTRP and evaluating treatments for Covid-19 to obtain their protocol and results as soon as available. We have received more than 130 responses that will feed into our living data visualization and mapping and will allow us to update our living systematic review.